SNDX - Company ID 0001395937
Syndax Pharmaceuticals Inc trades as SNDX and has a market capitalization of $2.09 B, making it the #2095 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $172.35M, up 627.8% from the prior year and net income of -$285.40M. This page tracks Syndax Pharmaceuticals Inc through 635 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-11
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Syndax Pharmaceuticals Inc's revenue grew from $1.22M to $172.35M, a compound annual growth rate of 73.3%. Net profit margin expanded from -3645.2% to -165.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-04-30 |
| Annual report to shareholders | ARS | 2026-04-30 |
| Proxy materials | DEFA14A | 2026-04-30 |
| Proxy statement | DEF 14A | 2026-04-30 |
| Quarterly report | 10-Q | 2026-04-30 |
| Major company event | 8-K | 2026-04-30 |
| SCHEDULE 13G/A | - | 2026-03-27 |
– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who
The Company will highlight its late-stage revumenib and axatilimab programs, including its ongoing trials in idiopathic pulmonary fibrosis, newly diagnosed chronic graft-versus-host disease, and newly diagnosed acute leukemia. Further, the Company will detail its new early-stage assets and broader plans to leverage its capabilities and resources to bring new treatment options to more patients.
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Jefferies Global Healthcare Conference in New York, NY with a fireside chat on Thursday, June 4, 2026 , at 9:20 a.m. ET .
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
The largest companies sharing Syndax Pharmaceuticals Inc's SEC industry classification (pharmaceutical preparations).
Syndax Pharmaceuticals Inc (SNDX) has a market capitalization of $2.09 B as of 2026-07-11, ranking #2095 among US-listed companies.
Syndax Pharmaceuticals Inc reported revenue of $172.35M for fiscal year 2025, an increase of 627.8% year over year.
In its latest fiscal year Syndax Pharmaceuticals Inc reported a net loss of $285.40M.